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ABSTRACT
Atopic dermatitis/eczema is a chronic inflam-
matory skin condition, and emollients are the
first-line treatment. Despite their widespread
use, there is uncertainty about the frequency
and type of adverse events associated with dif-
ferent emollients. We conducted a restricted
review of published data on adverse events
associated with emollient use in eczema. Med-
line (Ovid) was searched from inception (1946)
to June 2018. All types of studies, with the
exception of reviews, were included. Eligibility
was assessed using a two-stage screening process
against inclusion and exclusion criteria. Refer-
ences of all included papers were screened for
any additional eligible papers. Data were sub-
sequently extracted from all eligible publica-
tions. A limited body of data were found in the
published data: 24 papers reported on adverse
events with 29 different emollients (3
containing urea, 5 containing ceramide, 4 con-
taining glycerol, 4 were herbal and 13 contained
‘‘other’’ ingredients). Interpretation of the
results and comparison of the emollients were
difficult due to poor reporting and missing data.
Many publications contained no data at all on
adverse events, and no study reported serious
treatment-related adverse events for any emol-
lient. The proportion of participants in the
studies experiencing treatment-related adverse
events varied between 2 and 59%. The most
common adverse events were skin related and
often mild. The range of participants experi-
encing non-treatment-related adverse events
varied between 4 and 43%. From this restricted
review, clinicians and patients can be reassured
that the emollients studied appear to be gener-
ally safe to use. Better studies and reporting of
adverse events associated with emollients in
common use are needed.
Keywords: Adverse events; Emollients; Atopic
dermatitis; Atopic eczema; Moisturizers
INTRODUCTION
Atopic eczema (atopic dermatitis, hereafter
‘‘eczema’’) is a chronic inflammatory skin con-
dition characterized by red, itchy skin lesions
[1]. There is a stepwise approach to the treat-
ment of eczema, depending on disease severity
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and response [2]. Emollients are topical thera-
pies which act to ‘‘soothe, smooth and hydrate
the skin’’ [3]. They are the first-line treatment
for eczema across all severities and should be
used continually with and in larger quantities
than other topical treatments [2].
Given the widespread and long-term use of
emollients in treating eczema, an understand-
ing of just how common adverse events are
associated with emollients is important. How-
ever, the reporting of adverse events associated
with topical eczema therapies has focused on
the use of corticosteroids and calcineurin inhi-
bitors, such as tacrolimus [4, 5]. A recent
Cochrane review of emollients used to treat
eczema only included adverse event data from
randomized control trials (RCTs) [1].
The aim of this study was to conduct a
restricted review [6] into adverse events associ-
ated with the use of emollients in eczema.
METHODS
Literature Search
The Medline database (Ovid) was searched from
inception (1946) to June 2018 for adverse events
associated with emollient use in patients with
eczema. A search strategy was developed using
keywords from the electronic database, which
combined search terms for eczema, emollients
and adverse events (see Electronic Supplemen-
tary Material [ESM] Appendix 1). Duplicate
publications were removed, and one of the
authors (AB) assessed eligibility by screening
titles and abstracts against the inclusion and
exclusion criteria. All identified papers were
then obtained and read in full. References of all
included papers were screened for any addi-
tional eligible papers. When AB was uncertain
about the inclusion or exclusion of a paper, its
eligibility was discussed with a second author
(MR) and agreement was reached. The reasons
for exclusion were recorded.
Eligibility Criteria
Studies investigating ‘‘leave-on’’ emollients for
the treatment of participants with atopic
eczema/dermatitis of any age were included in
this restricted review and included RCTs, cohort
studies, case–control studies and case reports/
series. Studies excluded were: those not in
humans; those not published in English; those
in which the emollient was not used for the
treatment of eczema or was mixed with other
topical therapies for eczema (e.g. topical corti-
costeroids); and those in which adverse events
related to emollient use were not included in
the title or abstract.
Data Extraction
One author (AB) developed and piloted a data
extraction tool before applying it to all the
included papers. The main outcome measure of
interest was the frequency and nature of adverse
events associated with emollient use. Expected
adverse events related to emollient use included
pruritus, rash, erythema, pain, burning and
hypersensitivity. Type and name of emollient,
study type, setting, patient population and dis-
ease diagnostic criteria (if any) applied were also
recorded.
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not contain any studies with
human participants or animals performed by
any of the authors, so ethical approval was not
required.
RESULTS
Database Search
A total of 897 papers were initially identified;
following the removal of duplicate studies, 892
titles and abstracts were screened for eligibility.
The full text of 102 papers were then screened,
and 80 papers excluded. Two papers were added
from the references of the included papers
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which resulted in a total of 24 papers included
in the review (see Fig. 1).
Study Characteristics
The characteristics of the included papers are
summarized in Table 1. Most studies were RCTs
(17, 71%) [7–23], followed by non-randomized
interventional studies (5, 21%) [24–28]. There
was one cohort [29] and one case–control study
[30]. Most of the papers (13, 54%) did not specify
the settings in which the studies were conducted
[7, 11, 13, 14, 18–20, 22, 23, 25–27]; however,
ten studies took place in a specialist setting (7
secondary care centers [9, 10, 12, 15, 24, 28, 30],
2 research centers [8, 21] and 1 mobile derma-
tological center [16]). One study took place in
both a secondary care and a research centre [17].
No studies took place in a primary care/com-
munity setting (see Table 1).
There were ten (42%) studies involving just
children [10–12, 14, 15, 17, 18, 21, 27, 28], five
(21%) with only adults [7, 8, 19, 22, 23] and nine
(38%) involving both children and adults
[9, 13, 16, 20, 24–26, 29, 30]. Eleven (46%)
897 publicaons 
idenﬁed through 
Medline database 
search
892 tle and 
abstracts screened
102 publicaons
85 full texts 
reviewed
24 papers included
2 papers idenﬁed through 
reference screening
17 publicaons unavailable
(see appendix 2)
63 exclusions:
(reasons not mutually exclusive):
31 reviews/not in eczema/humans 
and/or reporng adverse events
32 not specifying vehcile/placebo
790 exclusions
(reasons not mutually exclusive):
442 not eczema; 669 not leave-on 
emollient; 693 not reporng adverse 
events; 41 not in human; 91 not in 
English; 13 no abstract
5 duplicates
Fig. 1 Flowchart of study selection
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Table 1 Characteristics of the papers included in the review
References Emollient(s) Study setting
(country)
Non-emollient
comparator
Patient
population
Eczema diagnostic
criteria
Chamlin et al.
[28]
TriCeram Cream Pediatric dermatology
clinics (USA)
– Stubborn-to-
recalcitrant
AD
Aged 1–12 years
n = 24
Unspeciﬁed
Chishti et al.
[30]
Dermovix ShifaulMulk
Memorial-Hospital
and Al-Rasheed
Darushifa Malkani
Liaqut Pur
(Pakistan)
Betnovate
N-Cream
AD
n = 60
Aged 2 years
to[ 40 years
Unspeciﬁed
Draelos [27] Atrapro
Antipruritic
HydroGel
Unspeciﬁed – Mild-moderate
AD
Aged
18–65 years
n = 17
Haniﬁn and Rajka
Draelos and
Raymond
[25]
NeoCera Unspeciﬁed – Mild-to-
moderate
atopic
dermatitis or
other xerotic/
pruritic
dermatoses
Aged 1–86 years
n = 50
Unspeciﬁed
Boguniewicz
et al. [21]
Atopiclair Cream 7 Study centers (US) ‘‘Vehicle’’
(unspeciﬁed)
AD
Aged 6 months
to 12 years
n = 142
Haniﬁn and Rajka
Boralevi et al.
[11]
Dexeryl (glycerol
containing
emollient)
Unspeciﬁed ‘‘Vehicle’’ AD
Aged 2–6 years
n = 251
UK Working Party
Dermatol Ther (Heidelb)
Table 1 continued
References Emollient(s) Study setting
(country)
Non-emollient
comparator
Patient
population
Eczema diagnostic
criteria
Bissonnette
et al. [7]
Iso-Urea (5% urea
moisturizer)
10% urea lotion
Unspeciﬁed – Mild-moderate
AD
Aged
18–70 years
n = 100
Unspeciﬁed
Gandy et al.
[13]
CHD-FA 3.5%
(carbohydrate-
derived fulvic
acid)
‘‘Placebo
emollient’’
(unspeciﬁed)
Unspeciﬁed – Eczema
[ 2 years
n = 36
Unspeciﬁed
Haider [10] 10% Sodium
cromoglycate
ointment
Placebo ointment
(white soft
parafﬁn)
Bury General
Hospital (England)
– Chronic atopic
eczema
Children
n = 42
Unspeciﬁed
Hashizume
et al. [23]
N-acetyl-
hydroxyproline
cream (AHYP;
contains glyerin
and glyceryl
stearate)
Unspeciﬁed ‘‘Control cream’’
(unspeciﬁed)
Slight AD
Aged
20–49 years
n = 14
Atopic dermatitis
treatment
guidelines of the
Japanese
Dermatological
Association
Hlela et al.
[12]
Cetomacrogrol
Emulsifying
ointment
Glycerine/
petroleum
Petroleum jelly
Red Cross Children’s
War Memorial
Hospital (South
Africa)
– Mild-moderate
AD
Aged 1–12 years
n = 80
UK Working Party
Kanehara et al.
[14]
Borage oil (coated
on undershirts)
Unspeciﬁed Non-coated
placebo
undershirts
Mild-moderate
AD
Aged 1–10 years
n = 32
Haniﬁn and Rajka
Dermatol Ther (Heidelb)
Table 1 continued
References Emollient(s) Study setting
(country)
Non-emollient
comparator
Patient
population
Eczema diagnostic
criteria
Korting et al.
[15]
Verum (pale
sulfonated shale
oil cream 4%)
Outpatient centrers
(Germany)
‘‘Vehicle’’ Mild-moderate
AD
Aged 0–12 years
n = 99
Unspeciﬁed
Korting et al.
[19]
Hamamelis
distillate
Unspeciﬁed Hydrocortisone
cream on the
other side
‘‘Drug-free vehicle’’
(unspeciﬁed)
Moderately
severe atopic
eczema
Aged
18–62 years
n = 72
Haniﬁn and Rajka
Lode´n et al.
[22]
Glycerin cream
Urea cream
Unspeciﬁed ‘‘Placebo’’
(unspeciﬁed)
AD
Adults
n = 197
Unspeciﬁed
Lynde and
Andriessen
[29]
CeraVe
Moisturizing
Cream
Unspeciﬁed – Mild-moderate
AD
Fitzpatrick skin
types I–III
Children and
adults
n = 151
Unspeciﬁed
Na et al. [26] Atobarrier Cream Unspeciﬁed – Mild-moderate
AD
Aged 5–19 years
n = 30
Unspeciﬁed
Ruzicka et al.
[20]
Ointment base
containing
propylene
carbonate
Unspeciﬁed 0.03% tacrolimus,
0.1% tacrolimus,
0.3% tacrolimus
Moderate-severe
AD
Aged
13–60 years
n = 215
Rajka and
Langeland
Seghers et al.
[24]
Curel Moisture
Cream
National Skin Center
(Singapore)
– Stable, mild-
moderate AD
Aged 7–60 years
n = 40
UK Working Party
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studies did not specify how the diagnosis of
eczema was confirmed [7, 8, 10, 13, 15, 22, 23,
25, 26, 29, 30]. Six (25%) of the studies used
Hanifin and Rajka criteria [9, 14, 18, 19, 21, 27]
and four (17%) used the UK Working Party’s
Group criteria [11, 12, 17, 24]. The eczema of
participants in one (4%) study was diagnosed by
a dermatologist [16], in one (4%) study diagnosis
was based on Rajka and Langeland criteria [20]
and in one (4%) study diagnosis was based on
criteria of the Japanese Dermatological Associa-
tion [23].
Emollient Type and Application
Across all 24 studies included in the review, 29
named emollients were evaluated (see Table 2).
The most common types of emollient were
creams (15, 52%) [9, 11, 12, 15, 16, 19, 21–26,
28, 29], lotions (3, 10%) [7, 17, 18] and
Table 1 continued
References Emollient(s) Study setting
(country)
Non-emollient
comparator
Patient
population
Eczema diagnostic
criteria
Shimelis et al.
[16]
10% Chamomile
hydro-alcoholic
extract cream
Mobile
dermatological
centers (Ethopia)
‘‘Placebo’’
(unspeciﬁed)
AD
Aged 1–78 years
n = 11
Dermatologist
determined
Simpson et al.
[8]
Cetaphil
Restoraderm
Pro-DERM Institute
(Germany)
Untreated area ‘‘Controlled AD’’
(no active
lesions in
target area)
Aged
18–65 years
n = 20
Unspeciﬁed
Stainer et al.
[17]
Altoderm lotion
(4% sodium
cromoglicate)
3 NHS hospital
outpatient clinics, 1
specialist clinical
research center
(England)
‘‘Placebo’’ (base
lotion alone)
AD
Aged 2–12 years
n = 114
UK Working Party
Tan et al. [9] ‘‘Triclosan-
containing
emollient’’
National Skin Center
(Singapore)
‘‘Vehicle’’ Mild-moderate
AD
Aged
12–40 years
n = 60
Haniﬁn and Rajka
Udompatajkul
and
Srisatwaja
[18]
Eucerin Soothing
Lotion 12%
omega
(Licochalcone)
Unspeciﬁed 1%
Hydrocortisone
lotion
Mild-moderate
AD
Aged 2–15 years
n = 30
Haniﬁn and Rajka
AD Atopic dermatitis
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Table 2 Studies according to emollient type and constituents
Type of
emollient
Number of
emollients
References Main constituents of emollient
Urea Ceramide Glycerol Herbala Otherb
Lotion 3 Bissonnette et al. [7] d
Stainer et al. [17] d
Udompatajkul and Srisatwaja
[18]
d
Cream 15 Chamlin et al. [28] d
Seghers et al. [24] d
Draelos and Raymond [25] d
Lynde and Andriessen [29] d
Boralevi et al. [11] d
Hashizume et al. [23] d
Hlela et al. [12] d
Lode´n et al. [22] d d
Korting et al. [19] d
Shimelis et al. [16] d
Korting et al. [15] d
Boguniewicz et al. [21] d
Na et al. [26] d
Tan et al. [9] d
Gel 1 Draelos [27] d
Ointment 4 Haider [10] d
Chishti et al. [30] d
Hlela et al. [12] d
Ruzicka et al. [20] d
Jelly 1 Hlela et al. [12] d
Coated
undershirt
1 Kanehara et al. [14] d
Unknown 4 Bissonnette et al. [7] d
Simpson et al. [8] d
Hlela et al. [12] d
Gandy et al. [13] d
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ointments (4, 14%) [10, 12, 30, 20]. In one study
the emollient was a gel [27], in one study it was
a ‘‘jelly’’ [12] and one study explored emollients
applied to a coated undershirt [14]. The for-
mulation of four (14%) emollients could not be
determined [7, 8, 12, 13].
When grouping the emollients according to
their provenance or humectants (Table 2), three
(10%) contained urea [7, 22], five (17%) con-
tained ceramide [8, 24, 25, 28, 29], four (14%)
contained glycerol [11, 12, 22, 23] and four
(14%) had a herbal basis [14, 16, 25, 30]. Thir-
teen (45%) were classified as ‘‘other’’
[9, 10, 12, 13, 15, 17, 18, 20, 21, 26, 27].
Adverse Events Associated With
Emollients According to Constituents
No serious treatment-related adverse events
were reported for any emollient. The proportion
of participants experiencing treatment-related
adverse events varied between 2.4 and 58.8%
[9, 11, 12, 15, 17, 20, 24, 26, 27]. The most
common adverse events were skin related and
often mild. The range of participants experi-
encing non-treatment-related adverse events
varied between 4.2 and 43.1% [11, 15, 17, 19, 20]
(see Table 3).
Urea-Containing Emollients
Participants using Iso-Urea or 10% urea lotion
[7] reported 21 adverse events not related to the
study treatment, including common colds and
headaches (Table A1, ESM Appendix 2). The five
treatment-related adverse events reported were
all related to the skin. There was one withdrawal
due to adverse events with participants using
Iso-Urea (erythema on eczema plaques) and two
withdrawals due to adverse events with partici-
pants using 10% urea lotion (irritant contact
dermatitis and pruritus). A study into urea
cream [22] only reported on adverse skin reac-
tions, which included smarting, stinging, itch-
ing and dryness/irritation. No serious adverse
events were reported for any of the urea-con-
taining emollients.
Ceramide-Containing Emollients
Of the five ceramide-containing emollients
evaluated, four (Cetaphil Restoraderm Body
Moisturizer [8], NeoCera [25], CeraVe Moistur-
izing Cream [29], TriCeram Cream [28]) were
not associated with any no treatment-related
adverse events (Table A2, ESM Appendix 2).
Seven participants using Curel Moisture Cream
[28] experienced pruritus and one experienced a
warm sensation after application. There was one
withdrawal due to adverse events from the use
of Curel Moisture Cream (worsening of rashes
and acneiform papules on the face). No serious
adverse events were reported for any of the
ceramide-containing emollients.
Glycerol-Containing Emollients
Of the four glycerol-containing emollients eval-
uated, treatment-related adverse events were
only not reported by participants usingN-acetyl-
hydroxyproline cream (AHYP) [23] (Table A3,
ESM Appendix 2). Three participants experi-
enced treatment-related adverse events using
Dexeryl [11] (mild to moderate erythema, burn-
ing, pruritus); one participant using glycerine/
Table 2 continued
Type of
emollient
Number of
emollients
References Main constituents of emollient
Urea Ceramide Glycerol Herbala Otherb
Total 29 3 5 4 4 13
a Herbal: Pale sulfonated shale oil cream 4% [15]; 10% chamomile hydro-alcoholic extract cream [16]; hamamelis distillate
[19]; Dermovix [30]
b Other: ‘‘Triclosan-containing emollient’’ [9]; CHD-FA 3.5% (carbohydrate-derived fulvic acid) [13]; borage oil [14]; 12%
omega (Licochalcone A Lotion) [18]; propylene carbonate [20]; 10% sodium cromoglycate ointment [10]; Altoderm lotion
(4% sodium cromoglicate) [17]
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petroleum (and baby oil as a soap substitute) [12]
experienced itching, although thiswas perceived
to be with associated with the baby oil. Partici-
pants using glycerin cream [22] only reported on
adverse skin reactions, which included smarting,
stinging, itching and dryness/irritation. Thirty-
one participants experienced non-treatment-re-
lated adverse events when usingDexeryl [11]. No
serious adverse events were reported for any of
the glycerol-containing emollients.
Herbal Emollients
Treatment-related or non-treatment-related
adverse events were not reported for three of the
four herbal emollients evaluated: Dermovix
[30], borage oil coated on undershirts [14] and
10% chamomile hydro-alcoholic extract cream
[16] (Table A4, ESM Appendix 2). In a study on
Hamamelis distillate [19], five participants
reported experiencing itching, erythema, sting-
ing, lichenification or dry skin. Across the two
treatment groups, there were three non-treat-
ment-related adverse events (herpes simplex
infection, cystitis and bronchitis). No serious
adverse events were reported for any of the
herbal emollients.
Other Emollients
Three of the 13 emollients classified as ‘‘other’’
(10% sodium cromoglycate ointment [10],
emulsifying ointment [12], Eucerin Soothing
Lotion 12% omega [18]) did not result in any
treatment-related adverse events (Table A5, ESM
Appendix 2). The range of treatment-related
adverse events reported was from 5.0 to 58.8%.
Three participants experienced transient pain
after the application of a triclosan-containing
emollient [9]. One participant using Cetoma-
crogrol (and baby oil as a soap substitute) [12]
and one participant using petroleum jelly (and
baby oil as a soap substitute) [12] experienced
itching; however this was perceived to be asso-
ciated with the baby oil. One participant with-
drew due to a treatment-related adverse event
(erythema after use) when using Atobarrier
Cream [26]. Ten participants experienced mild
post application skin dryness after the use of
Atrapro Antipruritic HydroGel [27]. The only
treatment-related adverse events reported after
use of CHD-FA 3.5% (carbohydrate-derived ful-
vic acid) emollient was a short-lived burning
sensation [13]. The use of Verum [15] resulted in
two withdrawals due to adverse events (itch,
erythema and spreading of the eczema). For
Altoderm lotion [17] there were seven reports of
treatment-related adverse events (erythema and
pruritus and application site burning) and one
report of an allergic reaction (stinging, itching,
redness, skin evolved into eczema). Fifteen
participants reported treatment-related adverse
events (sensation of burning at the site of
application, pruritus and erythema) when using
an ointment base containing propylene car-
bonate [20]. Ten adverse events were reported
by participants who had used MAS063DP
(Atopiclair) Cream [21].
Participants using seven of the emollients
(10% sodium cromoglycate ointment [10],
Cetomacrogrol [12], Emulsifying ointment [12],
petroleum jelly [12], Atrapro Antipruritic
HydroGel [27], CHD-FA 3.5% [13], Eucerin
Soothing Lotion 12% omega [18]) did not have
any non-treatment-related adverse events. The
range of non-treatment-related adverse events
was between 6 and 43%. Three participants
using Verum [15] reported non-treatment-re-
lated adverse events (bronchitis, worsened tee-
thing and concussion), and 22 participants
using Altoderm Lotion reported non-treatment-
related adverse events [17]. Seven participants
reported a non-treatment-related adverse event
(exacerbation of atopic dermatitis) when using
an ointment base containing propylene car-
bonate [20]. Fifty non-treatment-related adverse
events were reported by participants who used
MAS063DP (Atopiclair) Cream [21].
No serious treatment-related adverse events
were recorded in the ‘‘other’’ emollients. Bogu-
niewicz et al. [21] reported two serious (as
determined by the author) non-treatment-re-
lated adverse events (tonsillectomy and acute
asthma exacerbation); however, it was not pos-
sible to determine whether these occurred in
the treatment group (MAS063DP [Atopiclair]
Cream) or the vehicle group.
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DISCUSSION
Summary of Main Findings
Across the 24 studies identified, 29 emollients
were evaluated. Most of these 24 studies were
RCTs, and there was a mix of studies involving
children, adults or both. The location of many
studies was unspecified, but the most common
setting was specialist care. The criteria for diag-
nosing eczema was also not stated in many of
the papers. The most common type of emollient
was cream, with the formulation of some not
described.
No serious treatment-related adverse events
were reported for any of emollients. The pro-
portion of participants experiencing treatment-
related adverse events varied between 2.4 and
58.8% [9, 11, 12, 15, 17, 20, 24, 26, 27], and the
most common adverse events were skin related
and often mild. The range of participants expe-
riencing non-treatment-related adverse events
varied between 4.2 and 43.1% [11, 15, 17, 19, 20].
Strengths and Limitations
We believe this our review is the first review
with the specific aim to quantify and compare
the frequency of adverse events between differ-
ent emollients across all types of published
studies. We followed a ‘‘restricted review’’
approach [6] and were able to rapidly identify
and summarize relevant international publica-
tions involving all types of studies. However,
due to resource limitations we did not attempt
to apply any criteria to assess the quality of the
research that we identified. We found that few
studies reported on adverse events and of those
that did, data was generally of poor quality. It
was difficult to interpret results and compare
emollients due to missing data, confusion over
whether adverse events referred to the treat-
ment or control and inconsistency in reporting
by subject or total numbers of the adverse
event. Several studies compared the ‘‘active’’
emollient to a ‘‘vehicle,’’ but the extent to
which such a comparator is ‘‘inert’’ is arguable.
We adopted the descriptions of the emollients
given by the authors of the included papers at
face value and summarized these accordingly,
such as, for example, ‘‘urea containing,’’ ‘‘her-
bal’’. As a result, it is possible that some emol-
lients may have been ‘‘misclassified’’; however,
reporting of the original studies means we were
unable to better delineate similarities and dif-
ferences between the emollients.
Limitations of this review itself are the
searching of only one database, exclusion of
papers not written in English and inability to
retrieve the full text of some articles which
potentially could have been included. Restric-
tions to the search criteria (‘‘eczema’’ and ‘‘ad-
verse events’’) will have excluded a number of
potentially relevant studies in which emollients
were evaluated in people without eczema and in
those where data on adverse events are reported
in the manuscript but not the title or abstract.
This limitation has been confirmed by the
omission of some papers from the results of the
search strategy which were included in the
recent Cochrane Review [1]. Only one reviewer
screened all the titles/abstracts and retrieved
papers, but in cases of uncertainty, eligibility for
inclusion was discussed with another author.
The wide variation observed in the propor-
tion of participants experiencing an adverse
event across the included studies may reflect a
true difference between the different emol-
lients, the population studied, how different
researchers collected adverse event data and/or
the number of participants in the study. In
other words, we have presented adverse events
as proportions of the total number of partici-
pants in each study, but the smaller the
denominator, the greater the potential error
around that estimate.
Comparison with Existing Literature
In common with previous systematic reviews
that have included emollients for eczema, we
found that adverse reporting in studies of
emollients is poor and when reporting is pre-
sent, the data suggest that in general these
events are of low frequency and mild [1, 31].
Van Zuuren et al. [1] reported that the relative
risks of an adverse event from all emollients was
24 per 100 (95% confidence interval 19–30)
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participants compared with 23 per 100 with
vehicle, placebo or no moisturizer (10 RCTs,
1275 participants, follow-up range from 4 weeks
to 6 months) but that there were more adverse
events associated with urea-containing creams
(65 per 100 participants in 1 RCT in which 129
participants were compared with placebo) and
oat-containing moisturizers (9 per 100 partici-
pants in 1 RCT in which 173 participants were
compared with no moisturizer).
CONCLUSIONS
Due to the limitations of both this review and
the available literature, our findings should be
interpreted with caution. Nevertheless, they
provide a basis for further detailed research,
with recommendations for a full systematic
review of adverse effects associated with emol-
lient use and better design and reporting of
future studies that evaluate emollients, includ-
ing adverse events.
Based on the findings of this restricted
review, clinicians and patients can be reassured
that the emollients studied appear to be gener-
ally safe to use. However, the emollients
described in these studies are not in common
use in many countries. Until further data
become available, patients and clinicians
should be encouraged to report adverse events
via their national systems, such as the Yellow
Card scheme [32].
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